Jazz Pharmaceuticals to Showcase Breakthroughs in Solid Tumor Oncology Research at ESMO 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that it will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024, taking place from September 13-17, 2024, in…
Successful Completion of Initial Phase of Polio Campaign in Gaza
Over 187,000 children under ten in central Gaza received the novel oral polio vaccine type 2 (nOPV2) during the first phase of a two-round polio vaccination campaign held from September…
WHO Establishes New Collaborating Centre for Longitudinal Ageing and Life Course Studies
The World Health Organization (WHO) has officially designated the EngAGE Centre for Research in Ageing at Trinity College Dublin as its new Collaborating Centre for Longitudinal Studies on Ageing and…
Ascendis Pharma Announces Q2 2024 Financial Results
Ascendis Pharma A/S (Nasdaq: ASND) has released its financial results for the second quarter, which ended on June 30, 2024, alongside a business update. “The recent FDA approval of YORVIPATH…
Ascendis Pharma and Royalty Pharma Secure $150 Million Royalty Financing Deal
Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) announced that Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150…
Computational TROP2 Biomarker Predicts Outcomes for Datopotamab Deruxtecan in TROPION-Lung01 Phase III Trial
An exploratory analysis of the TROPION-Lung01 Phase III trial revealed that TROP2, as measured by AstraZeneca’s advanced computational pathology platform—quantitative continuous scoring (QCS)—was a predictor of clinical outcomes in patients…
AstraZeneca Completes Clinical Program for Breztri’s Transition to Eco-Friendly Propellant
AstraZeneca has finalized the studies supporting the regulatory filings for Breztri/Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) to transition to a new, next-generation propellant. This propellant has a 99.9% lower Global…
Roche’s Fenebrutinib Shows Near-Complete Disease Control in MS for 48 Weeks
Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to present new 48-week data on its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, at the 40th Congress of the European Committee…
Infinitamab Deruxtecan Shows Promising Response in Phase 2 Lung Cancer Trial
Interim results from the ongoing IDeate-Lung01 phase 2 trial show that ifinatamab deruxtecan (I-DXd) continues to deliver promising objective response rates in patients with pretreated extensive-stage small cell lung cancer…
Johnson & Johnson’s Battle Against Medical Counterfeiting
Stolen contact lenses sold through fake online pharmacies, prescription medications missing active ingredients, and surgical sutures made from substandard materials are just a few examples of counterfeit healthcare products that…
Weekly Insulin Efsitora Alfa Matches Daily Insulin in A1C Reduction
Eli Lilly and Company (NYSE: LLY) has announced positive results from two phase 3 clinical trials, QWINT-1 and QWINT-3, evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2…
Lilly and EVA Pharma Partner to Increase Baricitinib Availability in Low- and Middle-Income Countries
Eli Lilly and Company (NYSE: LLY) and EVA Pharma have announced a new partnership aimed at increasing access to baricitinib for an estimated 20,000 individuals across 49 low- and middle-income…